RPSG Ventures buys Clarionix for ₹0.01 crore in 2026

Deal overview: a new healthcare vehicle under RPSG Ventures

RPSG Ventures Limited has acquired 100% of Clarionix Healthcare Private Limited for a purchase consideration of ₹0.01 crore. The acquisition became effective on June 25, 2026, according to the company’s exchange filing. Clarionix is now a wholly-owned subsidiary of RPSG Ventures. The stated purpose of the acquisition is to explore new business opportunities in the medical sector. The move is tied to a broader board-approved restructuring involving the group’s hospital business. In the same set of disclosures, the board also cleared a composite scheme of arrangement involving Woodlands Multispeciality Hospital Limited (WMHL). The sequence of steps is designed to place healthcare operations under a dedicated subsidiary while keeping the overall structure within a listed framework.

What RPSG Ventures acquired and how it was structured

The board approved the acquisition of 10,000 equity shares of face value ₹10 each in Clarionix. This represents the entire equity share capital of the target entity. The filing notes that the transaction does not fall within related party transactions. It also states that no specific governmental or regulatory approvals were required for the acquisition itself. Clarionix was incorporated recently and, as disclosed, had nil turnover at the time of the acquisition. The company is engaged in establishing and managing medical care facilities. RPSG Ventures positioned the acquisition as a platform step, preceding the larger composite scheme involving WMHL.

Clarionix: newly incorporated, nil turnover, healthcare mandate

Clarionix Healthcare Private Limited was incorporated on May 20, 2026. As per the disclosure, the entity has nil turnover and was set up to undertake healthcare-related businesses. The exchange filing also describes the intended scope as covering facilities such as hospitals and nursing homes, along with other medical facilities. The company’s stated engagement is in establishing and managing medical care facilities. With RPSG Ventures now owning 100% of Clarionix, the group has a clean corporate vehicle for healthcare operations. The structure allows the hospital undertaking to sit within a subsidiary even as certain steps are executed at the listed parent level.

Composite scheme: merger of WMHL and transfer to Clarionix

RPSG Ventures’ board approved a composite scheme of arrangement among RPSG Ventures Limited, WMHL, and Clarionix. Under the scheme, WMHL will be amalgamated with RPSG Ventures, and subsequently dissolved. After the amalgamation, the Hospital & Nursing Undertaking will be transferred from RPSG Ventures to Clarionix on a slump sale basis. The consideration for the slump sale is ₹400 crore (also disclosed as ₹4 billion). The company said executing the restructuring through a single scheme would help ensure continuity of hospital licences, registrations, and contracts without disrupting operations. The filing also stated that the restructuring is intended to bring the healthcare business under a listed platform and improve access to capital for future expansion. It also highlighted dedicated management focus for the hospital business and ring-fencing healthcare operations from other businesses.

Consideration mechanics: OCRPS issuance, conversion and redemption

As consideration for the amalgamation, RPSG Ventures will issue 500 optionally convertible redeemable preference shares (OCRPS) of face value ₹10 each for every 1 equity share of face value ₹10 held in WMHL. Each OCRPS is convertible into 5 equity shares within 18 months from the date of allotment. If not converted within that window, the preference shares will carry a 6% per annum coupon, as per the disclosure, and be redeemed at par after 78 months (6.5 years). The preference shares will not be listed on stock exchanges. The filing also states that the shareholding pattern of RPSG Ventures will remain unchanged immediately upon the scheme becoming effective. However, if all OCRPS are converted, the post-scheme shareholding pattern would show promoters holding 68.91% and non-promoters holding 31.09% of the expanded equity capital of 50,799,909 shares.

Regulatory process and approvals cited

The composite scheme is subject to approvals from the National Company Law Tribunal (NCLT), stock exchanges, and the Securities and Exchange Board of India (SEBI). While the Clarionix acquisition itself was stated to require no specific governmental or regulatory approvals, the merger and slump sale steps are explicitly contingent on the scheme clearances. This means the ₹400 crore transfer and the OCRPS issuance mechanics will proceed only after the necessary regulatory and tribunal approvals. The company’s filing sets out the structure but also makes clear that implementation depends on these approvals.

Market and financial snapshot: quarter numbers and share move

For the March quarter, RPSG Ventures reported a consolidated net loss of ₹57.5 crore on revenues of ₹2,927 crore. Following the board decisions and disclosures, the company’s shares ended at ₹889.75 on the National Stock Exchange, up 3.7% from the previous close, as reported in the same news flow. The market move was reported alongside details of the restructuring and the intended benefits cited by the company.

Rainbow Investments disclosure on promoter holding encumbrance

Separately, Rainbow Investments Limited disclosed that it held 1,29,29,326 equity shares in RPSG Ventures Limited as of March 31, 2026. The entity confirmed that it did not create any encumbrance on these shares, directly or indirectly, during the financial year ended March 31, 2026, under SEBI regulations. The disclosure was presented as a confirmation of promoter holding status with no encumbrance created during the stated period.

Key facts table

Why the structure matters for the listed entity

The company’s filing frames the restructuring as a way to ring-fence healthcare operations from other businesses within RPSG Ventures’ portfolio. It also says the structure creates flexibility to induct strategic or financial investors at the subsidiary level. Another stated objective is to provide dedicated management focus to the hospital business. By transferring the Hospital & Nursing Undertaking to Clarionix after merging WMHL into the listed parent, the group aims to consolidate ownership and then place operating assets in the newly acquired subsidiary. The design also aims to keep operational continuity by preserving existing licences, registrations, and contracts through a single scheme execution.

Conclusion

RPSG Ventures has completed the acquisition of Clarionix for ₹0.01 crore and positioned the new subsidiary as the proposed home for its hospital and nursing undertaking. The larger restructuring, including the WMHL merger, OCRPS issuance, and the ₹400 crore slump sale transfer to Clarionix, will move ahead subject to NCLT, stock exchange, and SEBI approvals. The next concrete milestones will be the regulatory and tribunal steps required for the composite scheme to become effective.